The update season continues at Neurochecklists, and below are 100 more examples of checklists that we recently updated, along with the recent neurology papers that drove the updates:
1. ALZHEIMER’S DISEASE: INVESTIGATIONAL TREATMENTS
Ayton S, Barton D, Brew B, et al.
Deferiprone in Alzheimer disease: a randomized clinical trial.
JAMA Neurol 2025; 82:11-18
***
Faghihi-Kashani S, Yoshida A, Bozan F, et al.
Clinical characteristics of anti-synthetase syndrome: analysis from the CCASS Project.
Arthritis Rheumatol 2024 (Online ahead of print)
***
Lun F, Palaiodimou L, Katsanos AH, Tsivgoulis G, Turc G.
Intravenous thrombolysis or antiplatelet therapy for acute nondisabling ischemic stroke.
Eur Stroke J 2024:23969873241293323
***
4. ARACHNOID CYSTS: CLINICAL FEATURES
Bison HS, Janetos TM, Russell EJ, Volpe NJ.
Cranial nerve palsies in the setting of arachnoid cysts: a case series and literature review.
J Neuroophthalmol 2024; 44:242-246
***
5. ARTERIAL DOLICHOECTASIA: CLINICAL FEATURES
Reddy YM, Parida S, Murthy JMK.
Vertebrobasilar dolichoectasia presenting as spastic paraparesis.
Neurology 2024; 102:e209281
***
6. ATOGEPANT
Tassorelli C, Nagy K, Pozo-Rosich P, et al.
Safety and efficacy of atogepant for the preventive treatment of episodic migraine (ELEVATE)
Lancet Neurol 2024; 23:382-392
***
7. AUTOIMMUNE ENCEPHALITIS: CLINICAL FEATURES
Thakolwiboon S, Gilligan M, Orozco E, et al.
Autoimmune encephalitis: recovery, residual symptoms and predictors of long-term sequelae.
JNNP 2025 (Online ahead of print)
***
Sakai S, Kasuya M, Kobayashi Y, Nonaka K, Suzuki M, Machida A.
Bilateral bow-hunter’s stroke caused by sleeping in prone position: A case of recurrent posterior circulation infarction.
J Stroke Cerebrovasc Dis 2024; 33:108075
***
9. BRIVARACETAM
Kassoum A, Intravooth T, Wendling AS, Staack AM, Steinhoff BJ.
Psychiatric assessment prior to and after switch from levetiracetam to brivaracetam.
Seizure 2024; 117:193-197
***
Shang T, Sguigna PV, Pinho MC, et al.
Microenhancement as a biomarker for cerebral microbleed in inflammatory cerebral amyloid angiopathy
Neurology 2025; 104:e210258
***
Arciniega H, Jung LB, Tuz-Zahra F, et al.
Cavum septum pellucidum in former American football players: findings from the DIAGNOSE CTE Research Project.
Neurol Clin Pract 2024; 14:e200324
***
12. CERVICAL ARTERY DISSECTION: RISK FACTORS
Mayer-Suess L, Knoflach M, Peball T, et al.
Cervical artery tortuosity is associated with dissection occurrence and late recurrence
Stroke 2024 (Online ahead of print)
***
13. CHANTER SYNDROME
Sotiropoulos MG, Harrison DS, Zusman BE, Puccetti MV, Molyneaux BJ.
CHANTER syndrome: an under-recognized cause of reversible hydrocephalus after opioid overdose.
Neurol Sci 2024 (Online ahead of print)
***
Chen ZY, Shi Q, Xiao K, et al.
Multisite skin biopsies vs cerebrospinal fluid for prion seeding activity in the diagnosis of prion diseases.
JAMA Neurol 2024; 81:1263-1273
***
15. CLUSTER HEADACHE: CO-MORBID DISORDERS
Petersen AS, Kristensen DM, Westgate CSJ, et al.
Compensated hypogonadism identified in males with cluster headache: a prospective case-controlled study.
Ann Neurol 2024; 95:1149-1161
***
16. CMT TYPE 4: GENETIC SUBTYPES
Sadjadi R, Picher-Martel V, Morrow JM, et al.
Clinical characteristics of Charcot-Marie-Tooth Disease Type 4J.
Neurology 2024; 103:e209763
***
Sivera R, Pelayo-Negro AL, Jericó I, et al.
Expanding the clinical spectrum of DRP2-associated Charcot-Marie-Tooth Disease.
Neurology 2024; 102:e209174
***
18. COVID 19: PERIPHERAL FEATURES
McAlpine L, Zubair AS, Joseph P, Spudich S.
Case-control study of individuals with small fiber neuropathy after COVID-19.
Neurol Neuroimmunol Neuroinflamm 2024; 11:e200244
***
19. CRYOPYRIN ASSOCIATED PERIODIC FEVER SYNDROME
Mulazzani E, Böhm L, Christmann T, Krumbholz M, Kümpfel T, Havla J.
Optical coherence tomography assessment of disease activity in cryopyrin-associated periodic syndrome.
Eur J Neurol 2024; 31:e16301
***
20. CEREBRAL VEIN THROMBOSIS (CVT): CLINICAL FEATURES
Ranjan R, Ken-Dror G, Martinelli I, et al.
Coma in adult cerebral venous thrombosis: The BEAST study.
Eur J Neurol 2024; 31:e16311
***
21. DEJA VU
Alencar SD, Cendes F, de Morais ABCG, Ribeiro VCAF, Frota NAF, Pinto LF.
Déjà vu in idiopathic generalized epilepsy: A systematic review.
Seizure 2024; 118:53-57
***
22. DENGUE FEVER: NEUROLOGICAL FEATURES
Gupta J, Choudhary R, Gupta A, et al.
Acute necrotizing encephalopathy of childhood associated with dengue: good neurologic outcome despite a fulminant presentation.
Neurology 2024; 103:e209954
***
23. DRAVET SYNDROME: MANAGEMENT
Chen S, Li M, Huang M.
Vagus nerve stimulation for the therapy of Dravet syndrome: a systematic review and meta-analysis.
Front Neurol 2024; 15:1402989
***
24. DRUG-INDUCED PARKINSNISM: RISK FACTORS
Calzetti S, Negrotti A.
Permanent non-progressive cinnarizine and flunarizine-induced parkinsonism
J Neurol Sci 2023; 444:120526
***
LeWitt PA, Stebbins GT, Christensen KV, Tan R, Pretorius A, Thomsen M.
Buspirone and zolmitriptan combination for dyskinesia: a randomized, controlled, crossover study.
Mov Disord 2024; 39:613-618
***
26. EPILEPSY: PSYCHIATRIC MANIFESTAIONS
Thapa S, Panah MY, Vaheb S, et al.
Psychosis and schizophrenia among patients with epilepsy: A systematic review and meta-analysis.
Epilepsy Res 2024; 207:107452
***
27. ERDHEIM CHESTER DISEASE: CLINICAL FEATURES
Alkabie S, Diamond EL.
Erdheim-Chester disease masquerading as CLIPPERS.
Neurol Neuroimmunol Neuroinflamm 2024; 11:e200294
***
28. FAMILIAL PARTIAL EPILEPSY WITH VARIABLE FOCI
Meletti S, Duma GM, Burani M, et al.
Ictal and postictal central apnea in DEPDC5-related epilepsy.
Neurol Genet 2024; 10:e200183
***
29. FMTLE
Zubal R, Velicky Buecheler M, Sone D, et al.
Brain hypertrophy in patients with mesial temporal lobe epilepsy with hippocampal sclerosis and its clinical correlates.
Neurology 2025; 104(2):e210182
***
30. FRONTO-TEMPORAL DEMENTIA (FTD): CLINICAL FEATURES
Restrepo-Martínez M, Ramirez-Bermudez J, Chacon-Gonzalez J, Ruiz-Garcia R, Malik R, Finger E.
Defining repetitive behaviours in frontotemporal dementia.
Brain 2024; 147:1149-1165
***
Boogers A, Fasano A.
Functional movement disorders and deep brain stimulation: a review.
Neurol Clin Pract 2025; 15:e200367
***
32. GUILLAIN BARRE SYNDROME (GBS): PROGNOSIS
Min YG, Hong YH, Rajabally YA, Sung JJ.
Timing of intravenous immunoglobulin treatment and outcome in Guillain-Barré syndrome: Is time nerve?
Muscle Nerve 2024; 70:1215-1222
***
33. GENE-SPECIFIC EPILEPTIC ENCEPHALOPATHY: CLASSIFICATION
Ganesh VS, Riquin K, Chatron N, et al.
Neurodevelopmental Disorder Caused by Deletion of CHASERR, a lncRNA Gene.
N Engl J Med 2024; 391:1511-1518
***
34. GFAP ENCEPHALITIS: CLINICAL FEATURES
Shu Y, Huang R, Li Q, et al.
Autoimmune glial fibrillary acidic protein astrocytopathy is associated with HLA-A*3303 and HLA-DPB1*0501.
Ann Neurol 2024; 95:901-906
***
35. GIANT TUMEFACTIVE PERIVASCULAR SPACES
Mizutani H, Misumi Y, Ueda M.
Giant tumefactive perivascular spaces: longitudinal follow-up.
Neurology 2024; 103:e209643
***
Kone G, Kvantaliani N, Cucchiara B.
Spot sign in hemorrhagic transformation of ischemic stroke.
Ann Neurol 2024; 96:591-592
***
37. HEMICRANIA CONTINUA: CAUSES
Navarro CE.
Bilateral calcification of the Meckel cave causing hemicrania continua.
JAMA Neurol 2024; 81:886-887
***
38. HYPOTHALAMIC HAMARTOMA: MANAGEMENT
Sami L, Chipaux M, Ferrand-Sorbets S, et al.
Genetic insights into hypothalamic hamartoma: unraveling somatic variants.
Neurol Genet 2024; 10:e200180
***
39. IgLON5 ANTIBODY DISEASE: MANAGEMENT
Postuma R, Vorasoot N, St Louis EK, et al.
IGLON5 frequency in idiopathic REM sleep behavior disorder: a multicenter study.
Neurol Neuroimmunol Neuroinflamm 2024; 11:e200311
***
40. IMMUNE CHECKPOINT INHIBITOR (ICI) MYOPATHY
Beecher G, Pinal-Fernandez I, Mammen AL, Liewluck T.
Immune checkpoint inhibitor myopathy: the double-edged sword of cancer immunotherapy.
Neurology 2024; 103:e210031
***
41. LOW PRESSURE HYDROCEPHALUS
Duan S, Hu J.
Pathogenesis and management of low-pressure hydrocephalus: A narrative review.
J Neurol Sci 2024; 460:122988
***
42. LUMBOSACRAL PLEXOPATHY: CAUSES
Madduluri B, Shaik AJ, Kamani NB, Sultana RS, Uppin MS.
Clinical Reasoning: an unusual etiology of lumbosacral plexopathy in a patient with HIV.
Neurology 2024; 103:e209930
***
43. MOTOR NEURONE DISEASE (MND): DIFFERENTIAL DIAGNOSIS
Badihian N, Gatto RG, Satoh R, et al.
Clinical and neuroimaging characteristics of PLS with overlapping features of progressive supranuclear palsy.
Eur J Neurol 2024; 31:e16320
***
44. MOTOR NEURONE DISEASE (MND): MINOR GENETIC RISK FACTORS
De Decker M, Zelina P, Moens TG, B et al.
C21ORF2 mutations point towards primary cilia dysfunction in amyotrophic lateral sclerosis.
Brain 2024 (Online ahead of print)
***
45. MOTOR NEURONE DISEASE (MND): NON-GENETIC RISK FACTORS
Zhang J, Cao W, Xie J, et al.
Metabolic syndrome and risk of amyotrophic lateral sclerosis: insights from a large-scale prospective study.
Ann Neurol 2024; 96:788-801
***
46. MOTOR NEURONE DISEASE (MND): NON-INVASIVE VENTILATION
Grassano M, Koumantakis E, Manera U, et al.
Giving breath to motor neurons: noninvasive mechanical ventilation slows disease progression in ALS.
Ann Neurol 2024; 95:817-822
***
47. MOLYBDENUM COFACTOR DEFICIENCY: MANAGEMENT
Duan J.
A 2-year-old girl with molybdenum cofactor deficiency.
Neurology 2024; 102:e209317
***
48. MOTOR PREDOMINANT NEUROPATHY
Record CJ, O’Connor A, Verbeek NE, et al.
Recessive variants in PIGG cause a motor neuropathy with variable conduction block, childhood tremor, and febrile seizures
Ann Neurol 2025; 97:388-396
***
49. MULTIPLE SCLEROSIS (MS): AND BREASTFEEDING
Graham EL, Bove R, Costello K, et al.
Practical considerations for managing pregnancy in patients with multiple sclerosis: dispelling the myths.
Neurol Clin Pract 2024; 14:e200253
***
50. MULTIPLE SCLEROSIS (MS): CLINICAL FEATURES
Kraker JA, Xu SC, Flanagan EP, Foster R, Wang F, Chen JJ.
Ocular manifestations of multiple sclerosis: a population-based study.
J Neuroophthalmol 2024; 44:157-161
***
51. MULTIPLE SCLEROSIS (MS): CSF ANALYSIS
Marastoni D, Turano E, Tamanti A, et al.
Association of levels of CSF osteopontin with cortical atrophy and disability in early multiple sclerosis.
Neurol Neuroimmunol Neuroinflamm 2024; 11:e200265
***
52. MULTIPLE SCLEROSIS (MS): INVESTIGATIONAL TREATMENTS
Montalban X, Vermersch P, Arnold DL, et al.
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2)
Lancet Neurol 2024; 23:1119-1132
***
53. MULTIPLE SCLEROSIS (MS): MODIFIABLE RISK FACTORS
Ali R, Trier NH, Houen G, Frederiksen JL.
Epstein-Barr nuclear antigen 1 antibody-based indices are increased in patients with multiple sclerosis.
Mult Scler Relat Disord 2024; 92:106173
***
54. MULTIPLE SCLEROSIS (MS): MRI FEATURES
Borrelli S, Martire MS, Stölting A, et al.
Central vein sign, cortical lesions, and paramagnetic rim lesions for the diagnostic and prognostic workup of MS.
Neurol Neuroimmunol Neuroinflamm 2024; 11:e200253
***
55. MULTIPLE SCLEROSIS (MS): NEUROLOGICAL FEATURES
Hoffman EM, Brown L, Jolliffe E, Sechi E, Harmsen WS, Schilaty ND, Weinshenker BG.
McArdle sign and neck flexion-induced change in central motor conduction in multiple sclerosis.
Mult Scler 2024; 30:1830-1834
***
56. MULTIPLE SCLEROSIS (MS): PROGNOSTIC FEATURES
Wu J, Olsson T, Hillert JA, Alfredsson L, Hedström AK.
Association between alcohol consumption and disability accumulation in multiple sclerosis.
Neurol Neuroimmunol Neuroinflamm 2024; 11:e200289
***
57. MULTIPLE SCLEROSIS (MS): PROTECTIVE FACTORS
Quinn CM, Rajarajan P, Gill AJ, et al.
Neurologic outcomes in people with multiple sclerosis treated with immune checkpoint inhibitors for oncologic indications.
Neurology 2024; 103:e210003
***
58. MULTIPLE SYSTEM ATROPHY (MSA): INVESTIGATIONS
Pasquini J, Firbank MJ, Best L, et al.
Hypothalamic involvement in multiple system atrophy: a structural MRI study.
J Neurol Sci 2024; 460:122985
***
59. MUSK MYASTHENI GRAVIS: MANAGEMENT
Spagni G, Vincent A, Sun B, et al.
Serological markers of clinical improvement in MuSK myasthenia gravis.
Neurol Neuroimmunol Neuroinflamm 2024; 11:e200313
***
60. MYASTHENIA GRAVIS (MG): IMMUNOSUPPRESSION TREATMENT
Chan F, Hardy TA, Malik S, Ramanathan S, Riminton DS, Reddel SW.
Induction cyclophosphamide with maintenance immunosuppression in high-risk myasthenia gravis
JNNP 2024; 95:1096-1101
***
61. MYOTONIC DYSTROPHY: CLINICAL FEATURES
Shear MA, Penon-Portmann M, Shieh JT, et al.
Fetal brain MRI findings in myotonic dystrophy and considerations for prenatal genetic testing.
Neurol Genet 2024; 10:e200171
***
62. NEMALINE MYOPATHY: GENETICS
Shammas I, Alhammad R, Naddaf E.
Filamin C-associated nemaline myopathy.
Neurology 2024; 102:e209477
***
Skolka MP, Suanprasert N, Martinez-Thompson JM, et al.
Neurologic clinical, electrophysiologic, and pathologic characteristics of primary vs secondary neurolymphomatosis.
Neurology 2024; 103:e209777
***
64. NEUROSARCOIDOSIS: CRANIAL FEATURES
Iyer S, Palegar T, Ojha A.
Vocal cord palsy as the presenting manifestation of neurosarcoidosis.
Neurology 2024; 103:e209955
***
65. NIEMANN-PICK C DISEASE: TREATMENT
Bremova-Ertl T, Ramaswami U, Brands M, et al.
Trial of N-Acetyl-l-Leucine in Niemann-Pick disease type C.
N Engl J Med 2024; 390:421-431
***
66. NMDAR ENCEPHALITIS: CLINICAL FEATURES
Ribeiro L, Psimaras D, Vollhardt R, et al.
REM and NREM sleep parasomnia in anti-NMDA receptor encephalitis.
Neurol Neuroimmunol Neuroinflamm 2024; 11:e200203
***
67. NEUROMYELITIS OPTICA (NMO): MRI FEATURES
Dinoto A, Cacciaguerra L, Krecke KN, et al.
Cerebellar involvement in attacks of aquaporin-4-IgG positive neuromyelitis optica spectrum disorder.
Neurol Neuroimmunol Neuroinflamm 2025; 12:e200344
***
68. NEUROMYELITIS OPTICA (NMO): TREATMENT
Cree BAC, Kim HJ, Weinshenker BG, et al.
Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: the N-MOmentum trial.
Lancet Neurol 2024; 23:588-602
***
69. OCRELIZUMAB
Gans A, Verrengia EP, Ricchiuti E, Leva S, Brajkovic S, Colombo D, Mazzone A, Prelle A.
Ocrelizumab-associated cryptogenic organizing pneumonia in multiple sclerosis
Mult Scler 2024 21:13524585241295677
***
70. PARKINSN’S DISEASE (PD): PREMOTOR FEATURES
Flores-Torres MH, Hughes KC, Cortese M, et al.
Identifying individuals in the prodromal phase of Parkinson’s disease: a prospective cohort study.
Ann Neurol 2024 (Online ahead of print)
***
71. PARKINSON’S DISEASE (PD): GENETIC CLASSIFICATION
Gustavsson EK, Follett J, Trinh J, et al.
RAB32 Ser71Arg in autosomal dominant Parkinson’s disease: linkage, association, and functional analyses.
Lancet Neurol 2024; 23:603-614
***
72. PARKINSN’S DISEASE (PD): INVESTIGATIONAL TREATMENTS
Meissner WG, Remy P, Giordana C, et al.
Trial of lixisenatide in early Parkinson’s disease.
N Engl J Med 2024; 390:1176-1185
***
Silva L, Laranjinha I; Casais C; Samões R.
Subacute parkinsonism induced by immune checkpoint inhibitors.
Annals of Movement Disorders 2024; 7:224-226
***
74. REFLEX SEIZURES
Pascarella A, Sgrò D, Minasi D, et al.
Seizures when exiting a bath: a rare type of reflex epilepsy.
Neurology 2024; 103:e210025
***
75. REFRACTORY EPILEPSY: DRUG TREATMENTS
Falsaperla R, Collotta AD, Marino SD, S et al.
Drug resistant epilepsies: a multicentre case series of steroid therapy.
Seizure 2024; 117:115-125
***
76. REFRACTORY STATUS EPILEPTICUS: TREATMENT
García-Ruiz M, Rodríguez PM, Palliotti L, et al.
Ketamine in the treatment of refractory and super-refractory status epilepticus: experience from two centres.
Seizure 2024; 117:13-19
***
77. RESTLESS LEGS SYNDROME: CLINICAL FEATURES
Petramfar P, Jankovic J.
Medication refractory restless legs syndrome: real-world experience.
J Neurol Sci 2024; 463:123121
***
78. RITUXIMAB
Hallberg S, Evertsson B, Lillvall E, et al.
Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: a Swedish cohort study.
Eur J Neurol 2024; 31:e16331
***
Serafim AB, Olivé-Cirera G, Ortega-González Á, et al.
Antibodies against ZSCAN1 in pediatric and adult patients with non-paraneoplastic ROHHAD syndrome.
Neurol Neuroimmunol Neuroinflamm 2024; 11:e200276
***
Massimi L, Bianchi F, Benato A, Frassanito P, Tamburrini G.
Ruptured Sylvian arachnoid cysts: an update on a real problem.
Childs Nerv Syst 2023; 39:93-119
***
81. SCHISTOSOMAL MELORADICULOPATHY
Barreto MESF, Fraiman P, Silva Ribeiro GA, et al.
Schistosomiasis involving the conus medullaris.
Neurology 2025; 104:e210156
***
Xu F, Xu S.
Cognitive-behavioral therapy for negative symptoms of schizophrenia: A systematic review and meta-analysis.
Medicine (Baltimore) 2024; 103:e39572
***
83. SICKLE CELL DISEASE: NEUROLOGICAL FEATURES
Khatri D, Zampolin R, Fortunel A, Lee SK.
Unruptured intracranial aneurysms in pediatric sickle cell disease: clinical and MR imaging follow-up of 296 patients.
J Neurosurg Pediatr 2024; 34:585-590
***
84. SICKLE CELL DISEASE: TREATMENTS
Frangoul H, Locatelli F, Sharma A, et al.
Exagamglogene autotemcel for severe sickle cell disease.
N Engl J Med 2024; 390:1649-1662
***
85. SIPONIMOD
Miscioscia A, Rinaldi F, Pilotto E, Perini P, Gallo P.
Siponimod-related bilateral macular edema: a transient and completely reversible disorder.
J Neuroophthalmol 2024; 44:e6-e7
***
86. SLIPPERS
Tsibonakis A, Theodorou A, Korkolopoulou P, Tsivgoulis G.
Supratentorial lymphocytic inflammation with parenchymal perivascular enhancement responsive to steroids
Ann Neurol 2024; 95:407-409
***
87. SNAKE BITE TOXICITY: CLINICAL FEATURES
Sharma V, Nayak S, Pattnaik SS, Mohanty AP, Patro S.
Snake bite-induced leukoencephalopathy: a rare case.
Cureus 2024; 16:e55116
***
88. SPONTANEOUS INTRACRANIAL HYPOTENSION (SIH): TREATMENT
Callen AL, Friedman DI, Parikh S, et al.
Diagnosis and treatment of spontaneous intracranial hypotension: role of epidural blood patching.
Neurol Clin Pract 2024; 14:e200290
***
89. STIFF PERSON SYNDROME (SPS): TREATMENTS
Celli SI, Nash R, Money KM, et al.
Successful autologous hematopoietic stem cell transplant in glycine receptor antibody-positive stiff person syndrome.
Neurol Neuroimmunol Neuroinflamm 2024; 11:e200197
***
90. STROKE: SECONDARY PREVENTION
Escalera E, Saver JL.
Magnitude of effect of low dose colchicine, a newly food and drug administration approved treatment for stroke prevention.
J Stroke Cerebrovasc Dis 2024 (Online ahead of print)
***
91. STROKE: THROMBOLYSIS AGENTS
Palaiodimou L, Katsanos AH, Turc G, et al.
Tenecteplase vs alteplase in acute ischemic stroke within 4.5 hours: a systematic review and meta-analysis.
Neurology 2024; 103:e209903
***
92. SUBARACHNOID HAEMORRHAGE (SAH): COMPLICATIONS
Eter A, Yamamoto T, Koutrouvelis A, Yamamoto S.
The association between the location of subarachnoid hemorrhage and the occurrence of Takotsubo cardiomyopathy.
Cureus 2024; 16:e62533
***
93. SUDEP: CLINICAL INDICATORS
Harmata GI, Rhone AE, Kovach CK, et al.
Failure to breathe persists without air hunger or alarm following amygdala seizures.
JCI Insight 2023; 8:e172423
***
Lam NG, Ahmadpour A, Gimelfarb A, Nanda R, Ares WJ.
Epidural spinal cord compression due to extramedullary hematopoiesis: systematic reviewwith an illustrative case.
World Neurosurg 2024; 193:119-130
***
95. TRIGEMINAL NEURALGIA (TN): CLINICAL FEATURES
Risager Lykke M, Elser HC, Fuglsang CH, Farkas DK, Sørensen HT.
Trigeminal neuralgia and risk of cancer: A population-based cohort study.
Cephalalgia 2024; 44:3331024241292637
***
96. TTR AMYLOIDOSIS NEUROPATHY: TREATMENT
Fontana M, Berk JL, Gillmore JD, et al.
Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy.
N Engl J Med 2025; 392:33-44
***
97. TUMEFACTIVE MS: DIFFERENTIAL DIAGNOSIS
Aboseif A, Young NP, McKeon A.
Perivascular tumefactive neurosarcoidosis of the basal ganglia.
Neurology 2024; 103:e209899
***
98. VAGUS NERVE STIMULATION (VNS)
Moshref R, Burneo JG, Steven DA, et al.
Vagus nerve stimulation in lesional and non-lesional drug-resistant focal onset epilepsies.
Epilepsy Behav 2024; 159:109948
***
99. VALPROATE: ADVERSE EFFECTS
Crespo Pimentel B, Kuchukhidze G, Xiao F, et al.
Sodium valproate is associated with cortical thinning of disease-specific areas in juvenile myoclonic epilepsy.
JNNP 2024; 96:11-14
***
100. VEIN OF GALEN ANEURYSMAL MALFORMATION (VGAM)
Hale AT, Liu S, Huang F, et al.
Endoluminal biopsy for vein of Galen malformation.
Neurosurgery 2024; 95:1082-1088
***
The Neurology Lounge 